Trial Profile
Phase I Study of BAY 43-9006 (NSC 724772) [sorafenib] in Patients With Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 13 Apr 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
- 06 Nov 2010 Status changed from recruiting to active, no longer recruiting, according to the M.D. Anderson Cancer Center record.
- 06 Nov 2010 Status changed from recruiting to active, no longer recruiting, according to the M.D. Anderson Cancer Center record.